These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 34876050)

  • 1. Provider perspectives on the acceptability and tolerability of dolutegravir-based anti-retroviral therapy after national roll-out in Uganda: a qualitative study.
    Zakumumpa H; Kitutu FE; Ndagije HB; Diana NK; Ssanyu JN; Kiguba R
    BMC Infect Dis; 2021 Dec; 21(1):1222. PubMed ID: 34876050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient experiences of sexual dysfunction after transition to dolutegravir-based HIV treatment in mid-Western Uganda: a qualitative study.
    Zakumumpa H; Kiguba R; Ndagije HB; Ategeka G; Ssanyu JN; Kitutu FE
    BMC Infect Dis; 2022 Aug; 22(1):692. PubMed ID: 35971109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of overweight and obesity among adolescents living with HIV after dolutegravir - based antiretroviral therapy start in Kampala, Uganda.
    Nakatudde I; Katana E; Agnes Odongpiny EL; Nalugga EA; Castelnuovo B; Fowler MG; Musoke P
    AIDS Res Ther; 2024 Apr; 21(1):23. PubMed ID: 38637785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.
    Moore CL; Turkova A; Mujuru H; Kekitiinwa A; Lugemwa A; Kityo CM; Barlow-Mosha LN; Cressey TR; Violari A; Variava E; Cotton MF; Archary M; Compagnucci A; Puthanakit T; Behuhuma O; Saϊdi Y; Hakim J; Amuge P; Atwine L; Musiime V; Burger DM; Shakeshaft C; Giaquinto C; Rojo P; Gibb DM; Ford D;
    BMC Infect Dis; 2021 Jan; 21(1):5. PubMed ID: 33446115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda.
    Twimukye A; Laker M; Odongpiny EAL; Ajok F; Onen H; Kalule I; Kajubi P; Seden K; Owarwo N; Kiragga A; Armstrong-Hough M; Katahoire A; Mujugira A; Lamorde M; Castelnuovo B
    BMC Infect Dis; 2021 Nov; 21(1):1154. PubMed ID: 34774018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "It's only fatness, it doesn't kill": a qualitative study on perceptions of weight gain from use of dolutegravir-based regimens in women living with HIV in Uganda.
    Alhassan Y; Twimukye A; Malaba T; Myer L; Waitt C; Lamorde M; Colbers A; Reynolds H; Khoo S; Taegtmeyer M
    BMC Womens Health; 2022 Jun; 22(1):246. PubMed ID: 35729541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Community acceptability of dolutegravir-based HIV treatment in women: a qualitative study in South Africa and Uganda.
    Alhassan Y; Twimukye A; Malaba T; Orrell C; Myer L; Waitt C; Lamorde M; Kambugu A; Reynolds H; Khoo S; Taegtmeyer M
    BMC Public Health; 2020 Dec; 20(1):1883. PubMed ID: 33287795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High acceptability and viral suppression rate for first-Line patients on a dolutegravir-based regimen: An early adopter study in Nigeria.
    Abudiore O; Amamilo I; Campbell J; Eigege W; Harwell J; Conroy J; Jiboye J; Lufadeju F; Amole C; Wiwa O; Anweh D; Agbaji OO; Akanmu AS
    PLoS One; 2023; 18(5):e0284767. PubMed ID: 37196012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and factors associated with adverse drug events among patients on dolutegravir-based regimen at the Immune Suppression Syndrome Clinic of Mbarara Regional Referral Hospital, Uganda: a mixed design study.
    Namulindwa A; Wasswa JH; Muyindike W; Tamukong R; Oloro J
    AIDS Res Ther; 2022 Apr; 19(1):18. PubMed ID: 35366917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association between adherence to antiretroviral therapy and viral suppression under dolutegravir-based regimens: an observational cohort study from Uganda.
    Wagner Z; Wang Z; Stecher C; Karamagi Y; Odiit M; Haberer JE; Linnemayr S
    J Int AIDS Soc; 2024 Aug; 27(8):e26350. PubMed ID: 39155425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study).
    Waitt C; Orrell C; Walimbwa S; Singh Y; Kintu K; Simmons B; Kaboggoza J; Sihlangu M; Coombs JA; Malaba T; Byamugisha J; Amara A; Gini J; Else L; Heiburg C; Hodel EM; Reynolds H; Mehta U; Byakika-Kibwika P; Hill A; Myer L; Lamorde M; Khoo S
    PLoS Med; 2019 Sep; 16(9):e1002895. PubMed ID: 31539371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engendering health systems in response to national rollout of dolutegravir-based regimens among women of childbearing potential: a qualitative study with stakeholders in South Africa and Uganda.
    Alhassan Y; Twimukye A; Malaba T; Orrell C; Myer L; Waitt C; Lamorde M; Kambugu A; Reynolds H; Khoo S; Taegtmeyer M
    BMC Health Serv Res; 2020 Aug; 20(1):705. PubMed ID: 32738918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High acceptability and viral suppression of patients on Dolutegravir-based first-line regimens in pilot sites in Uganda: A mixed-methods prospective cohort study.
    Nabitaka VM; Nawaggi P; Campbell J; Conroy J; Harwell J; Magambo K; Middlecote C; Caldwell B; Katureebe C; Namuwenge N; Atugonza R; Musoke A; Musinguzi J
    PLoS One; 2020; 15(5):e0232419. PubMed ID: 32459822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unlocking the potential: exploring the impact of dolutegravir treatment on body mass index improvement in underweight adults with HIV in Malawi.
    Maphosa T; Dunga S; Makonokaya L; Woelk G; Maida A; Wang A; Ahimbisibwe A; Chamanga RK; Zimba SB; Kayira D; Machekano R
    BMC Public Health; 2024 May; 24(1):1321. PubMed ID: 38755632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of neuropsychiatric adverse events and associated factors among adult patients on dolutegravir attending Mulago ISS clinic.
    Mwebaza J; Meya D; Musiime V; Birungi C
    HIV Med; 2023 Apr; 24(4):491-501. PubMed ID: 36336827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Availability and stock-outs of paediatric antiretroviral treatment formulations at health facilities in Kenya and Uganda.
    Jacobs TG; Okemo D; Ssebagereka A; Mwehonge K; Njuguna EM; Burger DM; Colbers A; Suleman F; Mantel-Teeuwisse AK; Ooms GI
    HIV Med; 2024 Jul; 25(7):805-816. PubMed ID: 38499513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial.
    Amuge P; Lugemwa A; Wynne B; Mujuru HA; Violari A; Kityo CM; Archary M; Variava E; White E; Turner RM; Shakeshaft C; Ali S; Nathoo KJ; Atwine L; Liberty A; Bbuye D; Kaudha E; Mngqibisa R; Mosala M; Mumbiro V; Nanduudu A; Ankunda R; Maseko L; Kekitiinwa AR; Giaquinto C; Rojo P; Gibb DM; Turkova A; Ford D;
    Lancet HIV; 2022 Sep; 9(9):e638-e648. PubMed ID: 36055295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Body weight and blood pressure changes on dolutegravir-, efavirenz- or atazanavir-based antiretroviral therapy in Zimbabwe: a longitudinal study.
    Shamu T; Egger M; Mudzviti T; Chimbetete C; Manasa J; Anderegg N
    J Int AIDS Soc; 2024 Feb; 27(2):e26216. PubMed ID: 38332525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Viral suppression after transition from nonnucleoside reverse transcriptase inhibitor- to dolutegravir-based antiretroviral therapy: A prospective cohort study in Lesotho (DO-REAL study).
    Brown JA; Nsakala BL; Mokhele K; Rakuoane I; Muhairwe J; Urda L; Amstutz A; Tschumi N; Klimkait T; Labhardt ND
    HIV Med; 2022 Mar; 23(3):287-293. PubMed ID: 34632682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort.
    Mondi A; Cozzi-Lepri A; Tavelli A; Rusconi S; Vichi F; Ceccherini-Silberstein F; Calcagno A; De Luca A; Maggiolo F; Marchetti G; Antinori A; d'Arminio Monforte A;
    J Int AIDS Soc; 2019 Jan; 22(1):e25227. PubMed ID: 30663278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.